跳至主要内容
临床试验/ACTRN12624000017527
ACTRN12624000017527尚未招募3 期

The effect of 12 weeks Melatonin administration on depressive symptoms in youth with major depressive disorders - A Randomised, Placebo-controlled, Double-blinded Trial.

The University of Sydney0 个研究点目标入组 579 人开始时间: 2024年1月10日最近更新:
适应症

试验速览

阶段
3 期
状态
尚未招募
入组人数
579

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 30 Years(—)
性别
All

入选标准

  • Aged between 18 and 30 inclusive at the time of providing informed consent
  • Current MDD according to the Structured Clinical Interview for DSM-5 (SCID-5)
  • Quick Inventory of Depressive Symptomatology, Adolescent version, self-rated (QIDS-A-SR) score > 11, indicating moderate-to-severe MDD, within 14 days of the first treatment visit
  • Pittsburgh Sleep Quality Index score >5 (general sleep disturbance) and/or Epworth Sleepiness Scale score >10 (suggestive of hypersomnia) and/or self-reported delayed sleep phase (habitual bed-time between 02:00-06:00) or irregular sleep cycles
  • Ability to provide written informed consent (including both adequate intellectual capacity and fluency in the English language)

排除标准

  • History of psychosis or bipolar type I or II (assessed with SCID-5)
  • Use of any form of melatonin or melatonin agonist within six weeks of the first treatment visit
  • Self-reported significant impaired kidney/ liver function (i.e., liver/kidney disease diagnosed)
  • Self-reported autoimmune conditions (e.g. rheumatoid arthritis, post-organ transplant)
  • Risk of difficulty with blood collection (e.g., poor vein visibility, previous incidence of fainting/significant discomfort during blood collection)
  • Self-reported sleep, respiratory (e.g., sleep apnoea), neurological, or medical conditions that could contribute to sleep-wake dysfunction
  • Self-reported allergy to melatonin or Microcrystalline Cellulose
  • Self-reported pregnancy or breastfeeding
  • Recent initiation (past 3 months) of new medication
  • Presence of a substance use disorder of at least moderate severity (according to DSM-5) within the preceding 6 months
  • Acute suicidal behaviour (score of 6 on Comprehensive Assessment of At-Risk Mental States item 7.3)
  • Participation in another trial of a sleep or circadian therapy within one month of the trial commencing
  • Regular shift work within 60-days prior to entry into the study.
  • Recent transmeridian travel across two or more time zones in the past one month

研究者

相似试验